

Joint Announcement

S.S.H. Medical Limited (ACN 070 028 625) (ASX Code: **SSH**)

and

Cosmedics Australia Limited (ACN 002 862 017) (NSX Code: **CMA**)

The Directors of SSH and Cosmedics wish to announce that, subject to the shareholder approval of both Companies, agreement has been reached whereby Cosmedics will purchase the entire shareholding of the SSH wholly owned subsidiary, SSH Medical Workstation Pty Limited, for a total consideration of twelve million five hundred thousand (12,500,000) fully paid ordinary shares in Cosmedics.

SSH Medical Workstation Pty Limited is the subsidiary of SSH that developed the General Practice diagnostic workstation MediStation, which electronically captures the results of any of 12 medical diagnostic examinations it can perform and stores the results in patient specific folders for future retrieval and, where necessary, transfers the resultant records to remote locations.

SSH believes that the work done so far on the MediStation concept means that the workstation is the most advanced product of its type available. By holding an equity interest in Cosmedics, SSH will benefit from the potential future upside achieved in successful commercialisation of the MediStation, while limiting any future financial commitments.

Cosmedics has followed a path of investing in devices, having recently negotiated the purchase of the FDA and TGA approved Unijet retractable safety syringe and, in conjunction with its existing cosmetic enhancement business, will seek to attract further investment to commercialise the Unijet retractable safety syringe and the MediStation opportunities.

SSH has also recently announced it will be seeking shareholder approval for the purchase of Brisbane based Bio-Layer Pty Limited, a leading-edge Australian biotechnology company, that was incorporated to develop and commercialise a platform for the rapid design of novel materials for the biotechnology, diagnostics and pharmaceutical industries. The initial focus of the Bio-Layer business has been the provision of materials science based solutions that change the way in which immunoassays (clinical disease tests) are developed and to improve the performance of the assay (test) and reduce the manufacturing costs of diagnostic kits. The focus of SSH going forward will be on the development of the Bio-Layer technology.

It is expected that SSH and Cosmedics will both hold shareholder meetings in September 2005 and, if approved, for the transaction to be completed in October 2005.

Mr Kim McGrath
Chairman,
SSH Medical Limited

Dr Bronte Douglass
Chairman
Cosmedics Australia Limited

16th, August 2005

